Natera, Inc.
Natera, Inc. is a U.S.-based diagnostics company that develops and commercializes molecular testing products built on cell-free DNA and bioinformatics. Its tests are used across oncology, women’s health, and organ health, with operations centered in the United States and supported by laboratory partners and select international distribution arrangements.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaBlood-based molecular tests used to detect and monitor cancer, including MRD applications.
Prenatal and reproductive genetic tests sold through direct and partner channels.
Transplant-related tests used to assess organ rejection and post-transplant monitoring.
Cloud-based Constellation licensing and third-party laboratory workflows.
Tuotteet
Raportoitu · osuus liikevaihdosta- Products99,6 %
- Licensing and Other0,4 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
Natera sells to insurers, clinics, physician practices, medical centers, independent laboratories, reference laboratories, and laboratory distribution partners. It also serves research laboratories and pharmaceutical companies, especially for clinical trials and development-related testing. Reimbursement from in-network insurers is central to the commercial model because it supports broader adoption of the company’s tests.
They reimburse Panorama, Horizon, Signatera and other tests under in-network contracts, enabling scale and predictable pricing.
They order screening and diagnostic tests for patients in women’s health, oncology and organ health.
They distribute or run tests under partner and licensing models, extending market reach.
They buy clinical trial testing and related services for development and research programs.
Strategia
Natera’s strategy centers on expanding adoption of its core tests, especially Panorama, Horizon and Signatera, through direct sales, payer coverage and partner channels. The company also uses laboratory licensing and international partnerships to extend reach while keeping its proprietary molecular and bioinformatics platform at the center of the model. Scientific evidence generation, reimbursement access and product innovation are key to sustaining competitive differentiation.
Most revenue comes from the U.S., so deeper adoption drives scale and commercial leverage.
In-network coverage improves predictability and expands the addressable patient base.
Clinical validation and new products support adoption across oncology, women’s health and organ health.
Partnerships can expand geographic reach and laboratory access without building every channel directly.
Maantiede
Q1/2026Natera’s revenue base is overwhelmingly U.S.-centric, with the company disclosing that 95% of revenue came from U.S. direct sales in 2025 and 3% from U.S. laboratory partners. International revenue is small, at about 2% of revenue, and is generated through laboratory partners and other overseas sales. The company also has foreign-currency exposure, mainly in euros and Singapore dollars, from its non-U.S. business.
Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.
Riskit
Natera depends heavily on reimbursement, payer coverage and continued adoption of a small number of core tests, so changes in coverage or pricing can affect demand and realized revenue. The company also faces intellectual property disputes, partner dependence, data privacy exposure and supply-chain concentration in sequencing platforms and reagents. Because its business is diagnostics-based and highly regulated, clinical performance, regulatory compliance and reimbursement decisions are central to risk.
- Reimbursement and coverage riskVaikutus: KorkeaTodennäköisyys: Korkea
A large share of revenue depends on insurer coverage and in-network pricing for tests.
Kohdistuu - Product concentration riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company says most revenue comes from a few core tests, so weakness in one can affect the whole business.
Kohdistuu - Intellectual property litigationVaikutus: KorkeaTodennäköisyys: Kohtalainen
The molecular diagnostics field is patent-intensive and the company is involved in disputes with competitors.
Kohdistuu - Single-source supply dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
Validated sequencing platform and reagent supply concentration can disrupt test operations if interrupted.
Kohdistuu: Illumina sequencing platform and related reagents
- Third-party partner dependenceVaikutus: KeskitasoTodennäköisyys: Korkea
Laboratory partners and distributors can reduce control over commercialization, pricing and market access.
Kohdistuu: Women’s health distribution and international partnerships
- Data privacy and cybersecurityVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Patient data may be handled by vendors, licensees and cloud systems, creating breach and compliance risk.
Kohdistuu: Cloud-based Constellation model and third-party vendors
Kirjanpito
Harkinnanvaraiset erätDifferent billing paths and payer arrangements affect when and how revenue is recorded.
Vaikutus: Direct patient/insurer billing, partner billing and Constellation licensing
Performance-based awards materially affect operating expenses and reported loss.
Vaikutus: Non-cash compensation expense
Business combinations require valuation assumptions that can materially affect assets and future impairment risk.
Vaikutus: Developed technology intangible assets
Non-U.S. revenue and balances create gains and losses in other income/expense.
Vaikutus: Euro and Singapore dollar exposure
IP disputes and other claims can create uncertain liabilities and disclosure requirements.
Vaikutus: Patent infringement and partner disputes
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Septerna, Inc.
SEPN · Pharmaceutical Preparations
Septerna is a U.S.-based biotechnology company focused on discovering and developing small-molecule medicines for diseases driven by G protein-coupled receptors (GPCRs).
Danaher Corporation
DHR · Industrial Instruments For Measurement, Display, and Control
Danaher is a U.S.-based science and technology company organized around biotechnology, life sciences, and diagnostics.
Sotera Health Co
SHC · Services-Misc Health & Allied Services, NEC
Sotera Health is a U.S.-based provider of sterilization, laboratory testing, and advisory services for healthcare and life-science supply chains.
Biomerica, Inc
BMRA · In Vitro & In Vivo Diagnostic Substances
Azitra, Inc.
AZTR · Pharmaceutical Preparations
Veracyte, Inc
VCYT · Services-Medical Laboratories
Veracyte is a U.S.-based molecular diagnostics company that develops and commercializes genomic tests used in cancer and other disease areas.
Päivitetty: 24.9.2026